Comparison of long-term drug survival and safety of biologic agents in patients with psoriasis vulgaris

R Gniadecki, B Bang, L E Bryld, L Iversen, Stine Lasthein, L Skov

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Resumé

BACKGROUND: Drug survival (time to drug discontinuation) has recently emerged as an important parameter reflecting the long-term therapeutic performance in a real-life setting. Biologic drug survival in psoriasis is mainly limited by a gradual loss of efficacy over time. Previous studies have been limited by small patient population size and short observation times and yielded discrepant survival times for different biologics.

OBJECTIVES: To calculate the long-term drug survival for adalimumab, etanercept, infliximab and ustekinumab in a large cohort of real-life patients with psoriasis vulgaris and to analyse the factors that influence drug survival.

PATIENTS AND METHODS: Data were extracted from the prospective registry DERMBIO covering all patients with psoriasis vulgaris treated with biologic agents in the academic centres in Denmark. Drug survival was analysed using the Kaplan-Meier method. The influence of different covariates on drug survival was analysed by Cox regression.

RESULTS: Included in the analysis were 1867 treatment series (adalimumab n = 774, etanercept n = 449, infliximab n = 253, ustekinumab n = 391) administered in 1277 patients for up to 10 years. Drug survival was significantly longer for ustekinumab than for anti-tumour necrosis factor (TNF)-α agents (P < 0·001). Etanercept had the shortest survival time [median survival 30 months, 95% confidence interval (CI) 25·1-34·9] whereas adalimumab and infliximab had comparable survival rates (59 months, 95% CI 45·6-72·4; 44 months, 95% CI 33-54·9, respectively). Survival was longer in men [odds ratio (OR) 1·51, 95% CI 1·31-1·74 vs. women] and in patients who had not previously received any biologic agent (OR 1·24, 95% CI 1·05-1·46). Loss of efficacy accounted for 67% of all drug discontinuations.

CONCLUSIONS: Ustekinumab has a significantly longer drug survival than the anti-TNF-α agents. Switching from one biologic to another is associated with an impairment of drug survival. Preventing loss of efficacy is a major area of medical need in the biologic therapy of psoriasis and the strategies that improve drug survival should be further investigated.

OriginalsprogEngelsk
TidsskriftBritish Journal of Dermatology
Vol/bind172
Udgave nummer1
Sider (fra-til)244-52
ISSN0007-0963
DOI
StatusUdgivet - jan. 2015

Fingeraftryk

Psoriasis
Safety
Pharmaceutical Preparations
Confidence Intervals
Tumor Necrosis Factor-alpha
Odds Ratio
Denmark
Population Density
Statistical Factor Analysis
Registries
Survival Rate
Observation

Citer dette

Gniadecki, R ; Bang, B ; Bryld, L E ; Iversen, L ; Lasthein, Stine ; Skov, L. / Comparison of long-term drug survival and safety of biologic agents in patients with psoriasis vulgaris. I: British Journal of Dermatology. 2015 ; Bind 172, Nr. 1. s. 244-52.
@article{6539dfdc8c1d40e5a7c2f45bcecd6a38,
title = "Comparison of long-term drug survival and safety of biologic agents in patients with psoriasis vulgaris",
abstract = "BACKGROUND: Drug survival (time to drug discontinuation) has recently emerged as an important parameter reflecting the long-term therapeutic performance in a real-life setting. Biologic drug survival in psoriasis is mainly limited by a gradual loss of efficacy over time. Previous studies have been limited by small patient population size and short observation times and yielded discrepant survival times for different biologics.OBJECTIVES: To calculate the long-term drug survival for adalimumab, etanercept, infliximab and ustekinumab in a large cohort of real-life patients with psoriasis vulgaris and to analyse the factors that influence drug survival.PATIENTS AND METHODS: Data were extracted from the prospective registry DERMBIO covering all patients with psoriasis vulgaris treated with biologic agents in the academic centres in Denmark. Drug survival was analysed using the Kaplan-Meier method. The influence of different covariates on drug survival was analysed by Cox regression.RESULTS: Included in the analysis were 1867 treatment series (adalimumab n = 774, etanercept n = 449, infliximab n = 253, ustekinumab n = 391) administered in 1277 patients for up to 10 years. Drug survival was significantly longer for ustekinumab than for anti-tumour necrosis factor (TNF)-α agents (P < 0·001). Etanercept had the shortest survival time [median survival 30 months, 95{\%} confidence interval (CI) 25·1-34·9] whereas adalimumab and infliximab had comparable survival rates (59 months, 95{\%} CI 45·6-72·4; 44 months, 95{\%} CI 33-54·9, respectively). Survival was longer in men [odds ratio (OR) 1·51, 95{\%} CI 1·31-1·74 vs. women] and in patients who had not previously received any biologic agent (OR 1·24, 95{\%} CI 1·05-1·46). Loss of efficacy accounted for 67{\%} of all drug discontinuations.CONCLUSIONS: Ustekinumab has a significantly longer drug survival than the anti-TNF-α agents. Switching from one biologic to another is associated with an impairment of drug survival. Preventing loss of efficacy is a major area of medical need in the biologic therapy of psoriasis and the strategies that improve drug survival should be further investigated.",
author = "R Gniadecki and B Bang and Bryld, {L E} and L Iversen and Stine Lasthein and L Skov",
note = "{\circledC} 2014 British Association of Dermatologists.",
year = "2015",
month = "1",
doi = "10.1111/bjd.13343",
language = "English",
volume = "172",
pages = "244--52",
journal = "British Journal of Dermatology",
issn = "0007-0963",
publisher = "Wiley-Blackwell",
number = "1",

}

Comparison of long-term drug survival and safety of biologic agents in patients with psoriasis vulgaris. / Gniadecki, R; Bang, B; Bryld, L E; Iversen, L; Lasthein, Stine; Skov, L.

I: British Journal of Dermatology, Bind 172, Nr. 1, 01.2015, s. 244-52.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

TY - JOUR

T1 - Comparison of long-term drug survival and safety of biologic agents in patients with psoriasis vulgaris

AU - Gniadecki, R

AU - Bang, B

AU - Bryld, L E

AU - Iversen, L

AU - Lasthein, Stine

AU - Skov, L

N1 - © 2014 British Association of Dermatologists.

PY - 2015/1

Y1 - 2015/1

N2 - BACKGROUND: Drug survival (time to drug discontinuation) has recently emerged as an important parameter reflecting the long-term therapeutic performance in a real-life setting. Biologic drug survival in psoriasis is mainly limited by a gradual loss of efficacy over time. Previous studies have been limited by small patient population size and short observation times and yielded discrepant survival times for different biologics.OBJECTIVES: To calculate the long-term drug survival for adalimumab, etanercept, infliximab and ustekinumab in a large cohort of real-life patients with psoriasis vulgaris and to analyse the factors that influence drug survival.PATIENTS AND METHODS: Data were extracted from the prospective registry DERMBIO covering all patients with psoriasis vulgaris treated with biologic agents in the academic centres in Denmark. Drug survival was analysed using the Kaplan-Meier method. The influence of different covariates on drug survival was analysed by Cox regression.RESULTS: Included in the analysis were 1867 treatment series (adalimumab n = 774, etanercept n = 449, infliximab n = 253, ustekinumab n = 391) administered in 1277 patients for up to 10 years. Drug survival was significantly longer for ustekinumab than for anti-tumour necrosis factor (TNF)-α agents (P < 0·001). Etanercept had the shortest survival time [median survival 30 months, 95% confidence interval (CI) 25·1-34·9] whereas adalimumab and infliximab had comparable survival rates (59 months, 95% CI 45·6-72·4; 44 months, 95% CI 33-54·9, respectively). Survival was longer in men [odds ratio (OR) 1·51, 95% CI 1·31-1·74 vs. women] and in patients who had not previously received any biologic agent (OR 1·24, 95% CI 1·05-1·46). Loss of efficacy accounted for 67% of all drug discontinuations.CONCLUSIONS: Ustekinumab has a significantly longer drug survival than the anti-TNF-α agents. Switching from one biologic to another is associated with an impairment of drug survival. Preventing loss of efficacy is a major area of medical need in the biologic therapy of psoriasis and the strategies that improve drug survival should be further investigated.

AB - BACKGROUND: Drug survival (time to drug discontinuation) has recently emerged as an important parameter reflecting the long-term therapeutic performance in a real-life setting. Biologic drug survival in psoriasis is mainly limited by a gradual loss of efficacy over time. Previous studies have been limited by small patient population size and short observation times and yielded discrepant survival times for different biologics.OBJECTIVES: To calculate the long-term drug survival for adalimumab, etanercept, infliximab and ustekinumab in a large cohort of real-life patients with psoriasis vulgaris and to analyse the factors that influence drug survival.PATIENTS AND METHODS: Data were extracted from the prospective registry DERMBIO covering all patients with psoriasis vulgaris treated with biologic agents in the academic centres in Denmark. Drug survival was analysed using the Kaplan-Meier method. The influence of different covariates on drug survival was analysed by Cox regression.RESULTS: Included in the analysis were 1867 treatment series (adalimumab n = 774, etanercept n = 449, infliximab n = 253, ustekinumab n = 391) administered in 1277 patients for up to 10 years. Drug survival was significantly longer for ustekinumab than for anti-tumour necrosis factor (TNF)-α agents (P < 0·001). Etanercept had the shortest survival time [median survival 30 months, 95% confidence interval (CI) 25·1-34·9] whereas adalimumab and infliximab had comparable survival rates (59 months, 95% CI 45·6-72·4; 44 months, 95% CI 33-54·9, respectively). Survival was longer in men [odds ratio (OR) 1·51, 95% CI 1·31-1·74 vs. women] and in patients who had not previously received any biologic agent (OR 1·24, 95% CI 1·05-1·46). Loss of efficacy accounted for 67% of all drug discontinuations.CONCLUSIONS: Ustekinumab has a significantly longer drug survival than the anti-TNF-α agents. Switching from one biologic to another is associated with an impairment of drug survival. Preventing loss of efficacy is a major area of medical need in the biologic therapy of psoriasis and the strategies that improve drug survival should be further investigated.

U2 - 10.1111/bjd.13343

DO - 10.1111/bjd.13343

M3 - Journal article

VL - 172

SP - 244

EP - 252

JO - British Journal of Dermatology

JF - British Journal of Dermatology

SN - 0007-0963

IS - 1

ER -